Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression

被引:1
|
作者
Maretti-Mira, Ana C. [1 ]
Salomon, Matthew P. [1 ]
Chopra, Shefali [2 ]
Yuan, Liyun [1 ]
Golden-Mason, Lucy [1 ]
机构
[1] Univ Southern Calif, USC Res Ctr Liver Dis, Dept Med, Div Gastrointestinal & Liver Dis,Keck Sch Med, Los Angeles, CA 90033 USA
[2] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA
基金
美国国家卫生研究院;
关键词
metabolic dysfunction-associated steatotic liver disease (MASLD); innate immunity; transcriptomics; inflammation; metabolic dysfunction-associated steatohepatitis (MASH); neutrophils; FATTY LIVER-DISEASE; INNATE; CELLS; INFLAMMATION; MACROPHAGES; FIBROSIS; PROMOTES; BURDEN; SERVER; NAFLD;
D O I
10.3390/biomedicines12051105
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neutrophils play a crucial role in host defense against infection. Aberrant neutrophil activation may induce tissue damage via sterile inflammation. Neutrophil accumulation has been identified as a feature of the inflammatory response observed in metabolic dysfunction-associated steatohepatitis (MASH) and has been associated with liver fibrosis and cirrhosis. Here, we performed the transcriptomic analysis of circulating neutrophils from mild and advanced MASH patients to identify the potential mechanism behind neutrophil contribution to MASH progression. Our findings demonstrated that circulating neutrophils from mild and advanced MASH display an increased activated transcriptional program, with the expression of pro-inflammatory factors and an amplified lifespan compared to cells from non-diseased controls. Our results also suggest that MASH progression is associated with a dynamic shift in the profile of circulating neutrophils. In the early stages of MASH, mature neutrophils predominate in the bloodstream. As hepatic inflammation and fibrosis progress, the premature release of immature neutrophils into the circulation occurs. These immature neutrophils exhibit a pro-inflammatory profile that may exacerbate inflammation and promote fibrosis in MASH.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] The Biological Clock of Liver Metabolism in Metabolic Dysfunction-Associated Steatohepatitis Progression to Hepatocellular Carcinoma
    Rajan, Pradeep Kumar
    Udoh, Utibe-Abasi S.
    Finley, Robert
    Pierre, Sandrine V.
    Sanabria, Juan
    BIOMEDICINES, 2024, 12 (09)
  • [32] THERAPEUTIC HORIZONS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE( MASLD) & METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS( MASH): A SYSTEMATIC REVIEW OF CURRENT TREATMENT OPTION
    Moliya, Pratiksha
    Al-Obaidi, Hasan
    Patel, Pranav
    Patel, Raj
    Parikh, Charmy
    Joy, Melvin
    HEPATOLOGY, 2024, 80
  • [33] Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
    Younossi, Zobair M.
    Razavi, Homie
    Sherman, Michael
    Allen, Alina M.
    Anstee, Quentin M.
    Cusi, Kenneth
    Friedman, Scott L.
    Lawitz, Eric
    Lazarus, Jeffrey V.
    Schuppan, Detlef
    Romero-Gomez, Manuel
    Schattenberg, Joern M.
    Vos, Miriam B.
    Wong, Vincent Wai-Sun
    Ratziu, Vlad
    Hompesch, Marcus
    Sanyal, Arun J.
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025,
  • [34] New and emerging treatments for metabolic dysfunction-associated steatohepatitis
    Tincopa, Monica A.
    Anstee, Quentin M.
    Loomba, Rohit
    CELL METABOLISM, 2024, 36 (05) : 912 - 926
  • [35] Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitis
    Qin, Xueying
    Liu, Jingjing
    ACTA BIOMATERIALIA, 2024, 184 : 37 - 53
  • [36] The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis
    Charlton, Michael
    Tonnu-Mihara, Ivy
    Teng, Chia-Chen
    Zhou, Ziqi
    Asefaha, Feven
    Luthra, Rakesh
    Hoovler, Anthony
    Uzoigwe, Chioma
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 919 - 930
  • [37] Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis
    Kanwal, Fasiha
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 371 - 372
  • [38] Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
    Devasia, Arun George
    Ramasamy, Adaikalavan
    Leo, Chen Huei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (04)
  • [39] Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
    Loomba, Rohit
    Hartman, Mark L.
    Lawitz, Eric J.
    Vuppalanchi, Raj
    Boursier, Jerome
    Bugianesi, Elisabetta
    Yoneda, Masato
    Behling, Cynthia
    Cummings, Oscar W.
    Tang, Yuanyuan
    Brouwers, Bram
    Robins, Deborah A.
    Nikooie, Amir
    Bunck, Mathijs C.
    Haupt, Axel
    Sanyal, Arun J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 299 - 310
  • [40] Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis
    Marks, Lucas M.
    Jensen, Thomas
    DeGrado, Timothy R.
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (03):